Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report released on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Stock Down 2.1 %

NASDAQ:TENX opened at $4.22 on Friday. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $61.20. The stock has a 50-day simple moving average of $3.45 and a 200-day simple moving average of $3.78.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16. On average, equities analysts expect that Tenax Therapeutics will post -6.87 earnings per share for the current year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.